New England Biolabs UK Ltd CST - Cell Signaling Technology Biohelix Corp
Search:
Product CatalogueNew from New England Biolabs...Special OffersTechnical ResourcesContact UsMy Account
home > Product Catalogue > Cell Signaling Technology > TGF-beta Smad Signaling > MIS-R2 Antibody

MIS-R2 Antibody #4518

Catalog # Size & Concentration Price(£) Qty
4518S 100 ul (10 western blots) 172.00
Please contact us for bulks/custom orders/drug discovery applications

Applications Reactivity Sensitivity MW (kDa) Source
W IP H (Mk) Transfected Only 75-85 Rabbit

Applications Key:  W=Western Blotting  IP=Immunoprecipitation
Reactivity Key:  H=Human  Mk=Monkey
Species cross-reactivity is determined by Western blot.

Protocols

Specificity / Sensitivity

MIS-R2 Antibody detects transfected levels of human MIS-R2 protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu315 of human MIS-R2. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from COS cells, mock transfected or transfected with human myc-tagged MIS-R2, using MIS-R2 Antibody (construct kindly provided by Drs. David MacLaughlin and Patricia Donahoe, Massachusetts General Hospital).

Background

The type II receptor for Müllerian inhibiting substance (MIS), also known as the anti-Müllerian hormone receptor 2 (AMHR2), binds a hormone-ligand that directs the incomplete development of Müllerian ducts in male embryos (1,2). MIS-R2 is a single transmembrane serine/threonine kinase receptor of the TGF-β receptor family involved in the phosphorylation of shared type 1 receptors and Smad transcriptional regulators (3,4). MIS produced by the fetal testis promotes the regression of Müllerian ducts that would otherwise differentiate into the uterus and fallopian tubes in the male fetus (5). Corresponding MIS-R2 gene mutations can cause persistent Müllerian duct syndrome type 2 (PMDS-2), a form of male pseudohermaphroditism characterized by a failure of Müllerian duct regression (6). The presence of MIS-R2 is observed in ovarian cancer cell lines that respond positively to treatment with recombinant MIS, suggesting that both receptor and ligand may be important therapeutic tools (7).

  1. Visser, J.A. et al. (1995) Biochem Biophys Res Commun 215, 1029-36.
  2. di Clemente, N. et al. (1994) Mol Endocrinol 8, 1006-20.
  3. Teixeira, J. et al. (1996) Endocrinology 137, 160-5.
  4. Gouédard, L. et al. (2000) J Biol Chem 275, 27973-8.
  5. Jamin, S.P. et al. (2002) Nat Genet 32, 408-10.
  6. Imbeaud, S. et al. (1996) Hum Mol Genet 5, 1269-77.
  7. Masiakos, P.T. et al. (1999) Clin Cancer Res 5, 3488-99.
Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products


This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.